Avastin Eye Injection Cost: Why the Same Treatment Costs $165 Instead of $1,993
An Avastin (bevacizumab) eye injection is the cheapest anti-VEGF treatment by an order of magnitude: the drug costs the clinic about $50 to $70 a dose, against $1,444.50 for Eylea and $1,879.32 for Vabysmo at Medicare's own allowed amounts. A full visit runs about $165 to $185, so your 20% is roughly $33 to $37 instead of $312 or $399. Here is how it is billed, why it is this cheap, and the new branded version that would end the discount.
- At Medicare's rate, the bevacizumab in a 1.25 mg eye dose is worth about $9. The $50 to $70 the clinic pays is almost entirely the compounding pharmacy's work of splitting a cancer vial into sterile single-eye syringes.
- It is billed under J7999 at one unit per eye in a doctor's office, or C9257 in a hospital or surgery center. J7999 is priced by your regional Medicare contractor, so there is no single national number.
- Using it in the eye is off label but long established, and National Eye Institute trials found it worked about as well as ranibizumab for wet macular degeneration. For diabetic macular edema with worse starting vision, trials favored aflibercept, so it is genuinely case by case.
What It Costs Next to the Alternatives
The injection procedure is identical across all of these: CPT 67028, allowed $114.23 in a retina practice's office. Only the drug line changes. These are Medicare's allowed amounts for October 1 through December 31, 2026:
| Drug | Drug cost | Visit total | Your 20% |
|---|---|---|---|
| Avastin, compounded (1.25 mg) | $50 to $70 | $165 to $185 | $33 to $37 |
| Lucentis (0.5 mg) | $131.92 | $246.15 | $49.23 |
| Eylea (2 mg) | $1,444.50 | $1,558.73 | $311.75 |
| Vabysmo (6 mg) | $1,879.32 | $1,993.55 | $398.71 |
| Eylea HD (8 mg) | $2,327.22 | $2,441.45 | $488.29 |
Over a year of injections in one eye, that is the difference between about $210 and $2,930 of your own money on Original Medicare, where the 20% has no annual cap. Both eyes doubles it.
Source: CMS October 2026 Medicare Part B payment limit file (2Q26 ASP data) and the 2026 physician fee schedule (CPT 67028, 3.42 non-facility RVUs at the $33.4009 conversion factor). The compounded bevacizumab figure is the acquisition cost reported in the retina coding literature, because J7999 carries no national payment limit.
Want to know what your Avastin (bevacizumab) eye injection should cost you?
Costs vary substantially by procedure, location, facility, and insurance. Get a personalized estimate based on your situation.
Already have a bill? Send it to CareRoute and we will work to reduce it. 64% of cases reduced.
Why It Is This Cheap
Avastin was developed and priced as a cancer drug, given in doses measured in hundreds of milligrams. An eye needs 1.25 mg. A compounding pharmacy buys the vial and divides it into sterile single-eye syringes, so each patient pays for a sliver of a vial plus the pharmacy's work.
The arithmetic
- Medicare's limit for bevacizumab itself (code J9035) is $75.492 per 10 mg.
- An eye dose is 1.25 mg, so the molecule in your syringe is worth about $9.44.
- Clinics pay roughly $50 to $70 for the finished syringe. The rest is the compounding pharmacy's sterile preparation, testing, and shipping.
Nothing about this is a loophole. It is the only reason a patient on Original Medicare with no supplement can be treated indefinitely for a few hundred dollars a year instead of a few thousand.
How It Shows Up on Your Bill
Compounded drugs do not get a normal J code, which is why an Avastin eye injection looks different from every other drug on a statement:
| Setting | Drug code | Correct units |
|---|---|---|
| Doctor's office (Part B claim) | J7999 | 1 per eye, or 2 if both eyes at one visit |
| Hospital or surgery center (Part A claim) | C9257 | priced per 0.25 mg, so 5 for a 1.25 mg dose |
Because J7999 is the generic "compounded drug" code, your regional Medicare contractor sets what it pays rather than CMS publishing a national limit, and the claim is supposed to carry a note reading "Intravitreal bevacizumab, 1.25 mg" so the contractor knows what it is paying for. Three things worth checking:
- CPT 67028 once per eye, with an RT or LT modifier, or modifier 50 for both eyes. A one-eye visit billed as two is the most common error, and here it nearly doubles the bill because the drug is so cheap relative to the procedure.
- No J9035 line. If the statement shows J9035 at a cancer-sized unit count, the eye dose was billed as a full oncology dose.
- No hospital facility fee you did not need. The same injection in a hospital outpatient department adds a facility charge that can be larger than everything else on the claim combined.
The New Branded Version Changes This
Lytenava: the same molecule, with a list price
In July 2026 the FDA approved Lytenava (bevacizumab-vikg), the first bevacizumab formulated and approved specifically for injection into the eye. In September 2026 the manufacturer set its list price at $485 a vial. It is launching now and its permanent billing code is still pending with CMS.
The appeal is regulatory rather than clinical: an FDA-approved ophthalmic product instead of a compounded one, which removes the compounding pharmacy from the chain. The cost consequence for you is direct. Against a $50 to $70 compounded syringe, a $485 list price moves your 20% from a couple of dollars to roughly $97 a visit, or about $580 a year in one eye at six injections.
If your clinic tells you they are switching you from compounded Avastin to a branded bevacizumab, that is a reasonable thing to do and also a reasonable thing to ask about. The two questions worth asking: what is changing clinically, and what will my share be per visit.
Is It as Good? The Honest Answer
This is a medical decision, and the evidence does not point one way for every condition:
Wet macular degeneration
The National Eye Institute's head-to-head CATT trials found bevacizumab and ranibizumab produced similar vision outcomes. Many retina specialists start with bevacizumab for this reason and move to a branded drug if the response is not good enough.
Diabetic macular edema
Here the evidence favors aflibercept when starting vision is worse. If you have diabetic macular edema and your vision is already significantly reduced, the cheaper drug may not be the right one, and that is worth hearing from your specialist rather than deciding on price.
Off-label does not mean experimental
Intravitreal bevacizumab has been used for about two decades and Medicare contractors publish coverage policies for it. Off label here means the manufacturer never sought an FDA indication for eye use, not that the use is unproven or uncovered.
How to Pay Less
Raise the question before the first injection
If you are newly diagnosed, ask your retina specialist whether starting with bevacizumab is appropriate for your condition. It is the single largest lever on this bill, worth roughly $1,700 to $2,700 a year per eye against the branded drugs, and the answer may well be yes.
Keep it in the office
With a $60 drug, the facility fee becomes the dominant charge. The same injection in a retina practice's own office avoids it entirely. If a routine injection is being scheduled at a hospital clinic, ask whether the office can do it.
Uninsured: ask for the self-pay price in writing
This is the one anti-VEGF treatment a self-pay patient can realistically afford, but only if the clinic quotes a cash price rather than billing chargemaster rates. Ask for the self-pay rate for the drug and CPT 67028 together, up front, and ask about the practice's financial assistance policy at the same time.
Billed far more than these numbers?
A four-figure bill for a compounded Avastin injection means something is wrong: the wrong code, a doubled eye, a facility fee, or chargemaster pricing with no insurance applied. CareRoute Bill Defense reviews it and negotiates. Free to submit, and you only pay if we reduce it.
Frequently Asked Questions
How much does an Avastin eye injection cost?
The compounded 1.25 mg dose costs the clinic about $50 to $70, and the injection procedure (CPT 67028) is allowed $114.23 by Medicare in a doctor's office, so a visit comes to roughly $165 to $185. On Original Medicare your 20% is about $33 to $37. For comparison, the same visit with Eylea is allowed $1,558.73 and with Vabysmo $1,993.55. Because the drug is billed under the generic compounded-drug code J7999, your regional Medicare contractor sets the exact drug payment rather than CMS publishing a national figure.
Why is Avastin so much cheaper than Eylea or Vabysmo?
Avastin was developed and priced as a cancer drug given in doses of hundreds of milligrams, and an eye needs only 1.25 mg. At Medicare's rate for bevacizumab ($75.492 per 10 mg under code J9035) the molecule in one eye dose is worth about $9. A compounding pharmacy splits a vial into sterile single-eye syringes, and the $50 to $70 the clinic pays is mostly that preparation work. Eylea and Vabysmo are manufactured and priced specifically for the eye.
Does Medicare cover Avastin eye injections?
Yes. Medicare contractors publish coverage policies specifically for intraocular bevacizumab, and it is paid under Part B like the other anti-VEGF drugs: Medicare pays 80% of the allowed amount after the 2026 annual deductible of $283 and you owe 20%. Using it in the eye is off label, meaning the manufacturer never sought an FDA indication for that use, but it is covered and has been used for about two decades.
Is Avastin as effective as Eylea for the eye?
It depends on the condition. For wet macular degeneration, the National Eye Institute's CATT trials found bevacizumab produced vision outcomes similar to ranibizumab, and many specialists start there. For diabetic macular edema with worse starting vision, trial evidence favored aflibercept. This is a decision for your retina specialist, not a cost decision, but knowing the price gap lets you ask the question properly.
What code should an Avastin eye injection be billed under?
In a doctor's office, compounded intravitreal bevacizumab is billed under J7999 at one unit per eye (two if both eyes are injected at the same visit), with a note on the claim identifying it as intravitreal bevacizumab, 1.25 mg. In a hospital or surgery center it is billed under C9257, which is priced per 0.25 mg, so five units for a 1.25 mg dose. The injection itself is CPT 67028, once per eye, with an RT or LT modifier.
What is Lytenava and will it cost me more?
Lytenava (bevacizumab-vikg) is the first bevacizumab approved by the FDA specifically for injection into the eye, cleared for wet macular degeneration in July 2026. The manufacturer set its list price at $485 a vial in September 2026 and it is launching now, with its permanent billing code still pending. Clinically it is the same molecule most patients already receive compounded. On price, $485 against $50 to $70 moves your 20% from a couple of dollars to roughly $97 a visit, so it is worth asking what your share will be if your clinic switches you.
Related Guides
Sources
- CMS Medicare Coverage Database article A53008, Billing and Coding: Intraocular Bevacizumab, on billing compounded intravitreal bevacizumab under J7999 at one unit per eye with a claim note, and C9257 for Part A claims.
- CMS, October 2026 Medicare Part B Payment Limit File (ASP pricing file), effective October 1 to December 31, 2026, based on 2Q26 ASP data: J9035 bevacizumab $75.492 per 10 mg, J2778 $26.384 per 0.1 mg, J0178 $722.251 per 1 mg, J0177 $290.902 per 1 mg, J2777 $31.322 per 0.1 mg.
- CMS, 2026 National Physician Fee Schedule Relative Value File (October release): CPT 67028, 3.42 non-facility total RVUs, conversion factor $33.4009.
- Compounded intravitreal bevacizumab acquisition cost of roughly $50 to $70 per dose, as reported in the retina coding literature; J7999 is contractor priced and carries no national limit.
- National Eye Institute Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and the DRCR Retina Network comparative trial of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema.
- Outlook Therapeutics announcements: FDA approval of Lytenava (bevacizumab-vikg) for wet AMD, July 2026; $485 wholesale acquisition cost, September 2026; HCPCS code application submitted October 2026.
- CMS, 2026 Medicare Parts A and B premiums and deductibles (Part B deductible $283).
Because J7999 is priced by regional Medicare contractors, the drug payment for a compounded eye dose varies by area. Medicare payment limits for the other drugs are republished quarterly; these are the October to December 2026 figures. Which drug is right for you is a decision for you and your retina specialist. This is cost information, not medical advice. Last updated November 12, 2026.